Aug. 18 (Bloomberg) -- Brazil, the Latin American country with the largest HIV-infected population, is pressuring Abbott Laboratories to reduce prices of AIDS treatment Kaletra for the second time in a month, saying the government can make it for 59 percent less.
The country, as part of a decade-long fight to lower drug costs, reached an agreement with Abbott to reduce Kaletra's per- pill price to 99 cents from $1.17 on July 8. Three days later, President Luiz Inacio Lula da Silva named a new health minister, Saraiva Felipe, who demanded a bigger reduction. The government says it will manufacture the drug at a cost of 41 cents a pill if the fourth-largest U.S. drugmaker refuses.
The threat has prompted Abbott to delay plans to invest $27 million remodeling a plant in Brazil, a company spokeswoman said. U.S. Representative Mark Steven Kirk, a Republican from the district where the Abbott Park, Illinois-based company is located, said he would respond to a violation of Abbott's patent by proposing legislation to cancel trade preferences for $2 billion of Brazilian exports. <snip>
Brazil supplies drugs for free to as many as 163,000 victims of AIDS and HIV, the retrovirus that causes the disease. An estimated 23,400 people in Brazil use Kaletra, making it the drug's biggest market outside the developed world, Lotrowska said in a telephone interview from Sao Paulo. <snip>
http://www.bloomberg.com/apps/news?pid=10000086&sid=akUPDkm27vC8&refer=latin_america